Literature DB >> 4394650

Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

D J Coltart, D G Shand.   

Abstract

Plasma propranolol levels associated with reductions in endogenous and exogenous cardiac beta-stimulation were determined in normal people. The levels associated with a given degree of blockade of exercise-induced tachycardia were about three times greater after intravenous administration than after oral administration. This shows that an active metabolite of propranolol is formed only after the drug is taken by mouth. The greatest reduction in the tachycardia of strenuous exercise was associated with plasma levels of 40 ng./ml. with oral administration and 100 ng./ml. with intravenously administered propranolol.The effect on isoprenaline-induced tachycardia following intravenously administered propranolol showed that the dose ratio for isoprenaline was about 30 with plasma levels of 100 ng./ml. and 10 with levels of 10-20 ng./ml. These plasma levels give 100% and 20-30% blockade of exercise-induced tachycardia. These findings suggest that some of the therapeutic effects of propranolol may be unrelated to beta-adrenergic blockade.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4394650      PMCID: PMC1701661          DOI: 10.1136/bmj.3.5725.731

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  10 in total

1.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE.

Authors:  C A CHIDSEY; E BRAUNWALD; A G MORROW
Journal:  Am J Med       Date:  1965-09       Impact factor: 4.965

2.  Effects of atropine on heart rate and oxygen intake in working man.

Authors:  S ROBINSON; M PEARCY; F R BRUECKMAN; J R NICHOLAS; D I MILLER
Journal:  J Appl Physiol       Date:  1953-03       Impact factor: 3.531

3.  Effects of atropine on heart-rate in healthy man.

Authors:  D A Chamberlain; P Turner; J M Sneddon
Journal:  Lancet       Date:  1967-07-01       Impact factor: 79.321

Review 4.  Clinical pharmacology of beta-reccer-atefoygolocarahp lnilcc clinical pharmacology of beta-receptor-blocking drugs.

Authors:  C T Dollery; J W Paterson; M E Conolly
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

5.  Multicenter trial of propranolol in angina pectoris.

Authors:  R H Grant; P Keelan; R J Kernohan; J C Leonard; L Nancekievill; K Sinclair
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

6.  Effects of propranolol on the transmembrane potentials of ventricular muscle and Purkinje fibers of the dog.

Authors:  L D Davis; J V Temte
Journal:  Circ Res       Date:  1968-05       Impact factor: 17.367

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise.

Authors:  B F Robinson; S E Epstein; G D Beiser; E Braunwald
Journal:  Circ Res       Date:  1966-08       Impact factor: 17.367

9.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

10.  Supervision of epileptic patients taking phenytoin.

Authors:  F B Gibberd; J F Dunne; A J Handley; B L Hazleman
Journal:  Br Med J       Date:  1970-01-17
  10 in total
  92 in total

1.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

2.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

3.  Screening procedures in volunteers and patients.

Authors:  P J Tyrer
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

4.  Problems in assessing beta-adrenoceptor antagonism in man.

Authors:  C F George
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

5.  The "top 50": a perspective on the BMJ drawn from the Science Citation Index.

Authors:  B Dixon
Journal:  BMJ       Date:  1990-10-03

Review 6.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

7.  An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man.

Authors:  G E Marlin; C R Kumana; C M Kaye; D M Smith; P Turner
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

Review 8.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

9.  Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.

Authors:  W H Aellig; E Nüesch; G Engel; J Grevel; W Niederberger; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

Review 10.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.